Unknown

Dataset Information

0

A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress.


ABSTRACT: Human IgG comprises four subclasses with different biological functions. The IgG3 subclass has a unique character, exhibiting high effector function and Fab arm flexibility. However, it is not used as a therapeutic drug owing to an enhanced susceptibility to proteolysis. Antibody aggregation control is also important for therapeutic antibody development. To date, there have been few reports of IgG3 aggregation during protein expression and the low pH conditions needed for purification and virus inactivation. This study explored the potential of IgG3 antibody for therapeutics using anti-CD20 IgG3 as a model to investigate aggregate formation. Initially, anti-CD20 IgG3 antibody showed substantial aggregate formation during expression and low pH treatment. To circumvent this phenomenon, we systematically exchanged IgG3 constant domains with those of IgG1, a stable IgG. IgG3 antibody with the IgG1 CH3 domain exhibited reduced aggregate formation during expression. Differential scanning calorimetric analysis of individual amino acid substitutions revealed that two amino acid mutations in the CH3 domain, N392K and M397V, reduced aggregation and increased CH3 transition temperature. The engineered human IgG3 antibody was further improved by additional mutations of R435H to obtain IgG3KVH to achieve protein A binding and showed similar antigen binding as wild-type IgG3. IgG3KVH also exhibited high binding activity for Fc?RIIIa and C1q. In summary, we have successfully established an engineered human IgG3 antibody with reduced aggregation during bioprocessing, which will contribute to the better design of therapeutic antibodies with high effector function and Fab arm flexibility.

SUBMITTER: Saito S 

PROVIDER: S-EPMC6459999 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC3937676 | BioStudies
2020-01-01 | S-EPMC7077836 | BioStudies
2014-01-01 | S-EPMC3905167 | BioStudies
2017-01-01 | S-EPMC5459932 | BioStudies
2013-01-01 | S-EPMC3630167 | BioStudies
2008-01-01 | S-EPMC2585743 | BioStudies
2016-01-01 | S-EPMC5007037 | BioStudies
2020-01-01 | S-EPMC7326073 | BioStudies
2020-01-01 | S-EPMC7058349 | BioStudies
2018-01-01 | S-EPMC6160764 | BioStudies